EUCTR2007-006715-22-GB进行中（未招募）1 期
A Phase 2, Open-label Study of IMC-1121B in Combination with Paclitaxel and Carboplatin as First-line Therapy in Patients with Stage IIIB/IV Non-small Cell Lung Cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- ImClone LLC
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. The patient has histologically or cytologically confirmed NSCLC. Mixed NSCLC
- •tumors will be categorized by the predominant cell type. Cytologic or histologic
- •elements can be established on metastatic tumor aspirates or biopsy. For squamous
- •histology or for centrally located mediastinal masses (< 3 cm from the carina) identified by computed tomography scan (CT) or chest X-ray, the patient must undergo a magnetic resonance imaging (MRI) of the chest or intravenous contrast CT scan within 4 weeks of anticipated study entry, to exclude major airway or blood vessel invasion (in the investigator’s opinion) by cancer.
- •2. The patient has advanced NSCLC (Stage IIIB not suitable for radiation therapy or
- •chemoradiotherapy at study entry, or Stage IV). Patients with an earlier stage of disease that has relapsed with a higher stage are eligible provided chemotherapy or radiation therapy for pre-relapsed disease was completed > 1 year prior to study entry.
- •3. The patient has measurable disease (as defined by Response Evaluation Criteria in Solid Tumors [RECIST], see Section 11 of protocol).
- •4. The patient’s ECOG performance status is = 1.
- •5. The patient’s age at the time of study entry is = 18 years.
- •6. The patient has adequate hematologic function as defined by an absolute neutrophil count (ANC) = 1500/µL, hemoglobin = 9 g/dL, and a platelet count = 100,000/µL obtained within 2 weeks prior to the first dose of study medication.
- •7. The patient has adequate hepatic function as defined by a total bilirubin = 1.5 mg/dL (except for known Gilbert’s disease) and transaminases and alkaline phosphatase = 5 x the upper limit of normal (ULN) obtained within 2 weeks prior to the first dose of study medication.
- •8. The patient has adequate renal function as defined by serum creatinine = 1.5 x ULN or calculated creatinine clearance (CrCl) > 60 mL/minute, and urine dipstick for protein < 1+ (ie, either 0 or trace) obtained within 2 weeks prior to the first dose of study medication. If urine dipstick is = 1+, a 24-hour urine for protein must demonstrate < 500 mg of protein in 24 hours to allow participation in the study.
- •9. The patient has adequate coagulation function, as defined by international normalized ratio (INR) = 1.5 and a partial thromboplastin time (PTT) = 5 seconds above ULN if not receiving anticoagulation therapy. Patients on full-dose anticoagulation must be on a stable dose of oral anticoagulant or low molecular weight heparin, and if on warfarin must have therapeutic INR and have no active bleeding (defined as within 14 days of first dose of study medication) or pathological condition that carries a high risk of bleeding (eg, tumor involving major vessels or known varices).
- •10. The patient agrees to use adequate contraception during the study period and for 4 weeks after the last dose of study medication.
- •11. The patient has provided signed informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. The patient has untreated central nervous system (CNS) metastases. Patients with treated brain metastases are eligible if they have no evidence of Grade = 1 CNS hemorrhage based on pretreatment MRI or intravenous contrast CT scan (performed within 28 days prior to the first dose of IMC-1121B), are clinically stable with regard to neurologic function, and are off all steroids after cranial irradiation (whole brain radiation therapy, focal radiation therapy, stereotactic radiosurgery) ending at least 2 weeks prior to the first dose of IMC-1121B, or after surgical resection performed at least 4 weeks prior the first dose of IMC 1121B.
- •2. The patient received prior bevacizumab therapy.
- •3. The patient has radiologically documented evidence of major blood vessel invasion or encasement by cancer.
- •4. The patient received prior systemic chemotherapy for Stage IIIB/IV NSCLC.
- •5. The patient received prior systemic chemotherapy or radiation therapy for Stage I-IIIA NSCLC < 1 year prior to the first dose of study medication.
- •6. The patient has any concurrent malignancy other than basal cell skin cancer, or
- •carcinoma in situ of the cervix. Patients with adequately treated cancers of other
- •histologies who have been disease-free for more than 3 years prior to the first dose of study medication are eligible.
- •7. The patient is receiving concurrent treatment with other anticancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, radiotherapy, chemoembolization, or targeted therapy.
- •8. The patient has an ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •9. The patient has uncontrolled thrombotic or hemorrhagic disorders.
- •10. The patient has poorly-controlled hypertension (ie, blood pressure in abnormal range despite medical management).
- •11. The patient is receiving chronic daily treatment with aspirin (> 325 mg/day) or other known inhibitors of platelet function.
- •12. Patients with a history of gross hemoptysis (defined as bright red blood or = 1/2 teaspoon) within 2 months of entry into this trial.
- •13. The patient has had a serious non-healing wound, ulcer, or bone fracture within 28 days prior to first dose of study medication.
- •14. The patient has undergone major surgery with 28 days prior the first dose of study medication, or subcutaneous venous access device placement within 7 days prior to the first dose of study medication. Furthermore, any patients with post-operative bleeding complications or wound complications from surgical procedures performed in the last 2 months will be excluded.
- •15. The patient has an elective or a planned major surgery to be performed during the course of the trial.
- •16. The patient has peripheral neuropathy = Grade 2 (National Cancer Institute Common Toxicity Criteria for Adverse Events, Version 3.0 [NCI-CTCAE v 3.0]).
- •17. The patient, if female, is pregnant or lactating.
- •18. Regardless of tumor histology, the patient has radiographic evidence of intratumor cavitation.
- •19. The patient has experienc
研究者
相似试验
进行中（未招募）
1 期
Phase II Randomized, Open-Label Study of IMC-1121B With or Without Dacarbazine in Patients with Metastatic Malignant MelanomaMetastatic Malignant MelanomaMedDRA version: 9.1 Level: LLT Classification code 10027480 Term: Metastatic malignant melanomaEUCTR2007-006713-16-GBImClone Systems Incorporated104
进行中（未招募）
不适用
BI 207127 / faldaprevir combination therapy in hepatic impairment (Child-Pugh B) patients with genotype 1b chronic hepatitis C infectioChronic Hepatitis C InfectionEUCTR2012-003534-17-DEBoehringer Ingelheim Pharma GmbH & Co. KG35
进行中（未招募）
不适用
A Study of MM-111 and Paclitaxel with or without Trastuzumab in patients with Metastatic or Locally Advanced Cancer of the Esophagus, Gastroesophageal Junction and StomachHER2 distal esophageal, Gastroesophageal (GE) junction or gastric carcinoma.MedDRA version: 16.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: LLTClassification code 10015362Term: Esophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: LLTClassification code 10056267Term: Gastroesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003798-25-GBMerrimack Pharmaceuticals Inc.180
进行中（未招募）
1 期
A Study of MM-111 and Paclitaxel with Trastuzumab in patients with Metastatic or Locally Advanced Cancer of the Esophagus, Gastroesophageal Junction and StomachEUCTR2012-003798-25-DKMerrimack Pharmaceuticals Inc.151
进行中（未招募）
不适用
A Study of MM-111 and Paclitaxel with or without Trastuzumab in patients with Metastatic or Locally Advanced Cancer of the Esophagus, Gastroesophageal Junction and StomachHER2 distal esophageal, Gastroesophageal (GE) junction or gastric carcinoma.MedDRA version: 16.0Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0Level: LLTClassification code 10015362Term: Esophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0Level: LLTClassification code 10056267Term: Gastroesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-003798-25-ESMerrimack Pharmaceuticals Inc.180